Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

Sanofi India net profit down 46% in quarter ended September 30: Our Bureau, New Delhi Friday, November 8, 2024, 11:35 Hrs [IST] Sanofi India has registered 46 per cent decline in ...

Opella is Sanofi’s consumer healthcare business unit focusing on over-the-counter medicines, vitamins, minerals, and supplements and includes brands such as Allegra, Doliprane, and Dulcolax.

US-based investment firm takes controlling stake in Opella, while France's government moves to ensure the company remains in ...

Sanofi has entered exclusive negotiations to sell a 50% controlling stake in its consumer health business ... Opella, which houses brands including Allegra, generated sales of $5.7 billion ...

Sanofi Consumer Health Care India Ltd, the pharmaceutical company that makes Combiflam among other consumer drugs, announced to sell 26% of its equity shares to Opal Bidco SAS along with U.S ...

The drugmaker this week raised its annual profit forecast when announcing exclusive negotiations with US buyout firm Clayton Dubilier & Rice for the sale of its consumer health unit. Chief executive ...

I WAS SPECIFICALLY LOOKING FOR BRANDS THAT WERE KNOWN TO BE DURABLE, HAVE GREAT SAFETY QUALIFICATIONS, AND SOMETHING THAT WAS FUEL EFFICIENT. CONSUMER REPORTS JUST RELEASED ITS FIRST EVER BRAND ...

Lifestyle and clothing brands in India are seeing strong consumer demand as the festive season progresses. Brands like Raymond Lifestyle, Blackberrys, Libas are optimistic about sales growth ...

The French government has warned the United States investment company buying the consumer healthcare division of drugmaker ...